Julie Harnischfeger , Mandy Beutler , Denise Salzig , Stefan Rahlfs , Katja Becker , Christoph G. Grevelding , Peter Czermak
{"title":"Biochemical characterization of the recombinant schistosome tegumental protein SmALDH_312 produced in E. coli and baculovirus expression vector system","authors":"Julie Harnischfeger , Mandy Beutler , Denise Salzig , Stefan Rahlfs , Katja Becker , Christoph G. Grevelding , Peter Czermak","doi":"10.1016/j.ejbt.2021.08.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The heterologous expression of parasitic proteins is challenging because the sequence composition often differs significantly from host preferences. However, the production of such proteins is important because they are potential drug targets and can be screened for interactions with new lead compounds. Here we compared two expression systems for the production of an active recombinant aldehyde dehydrogenase (SmALDH_312) from <em>Schistosoma mansoni</em>, which causes the neglected tropical disease schistosomiasis.</p></div><div><h3>Results</h3><p>We produced SmALDH_312 successfully in the bacterium <em>Escherichia coli</em> and in the baculovirus expression vector system (BEVS). Both versions of the recombinant protein were found to be active <em>in vitro</em>, but the BEVS-derived enzyme showed 3.7-fold higher specific activity and was selected for further characterization. We investigated the influence of Mg<sup>2+</sup>, Ca<sup>2+</sup> and Mn<sup>2+</sup>, and found out that the specific activity of the enzyme increased 1.5-fold in the presence of 0.5 mM Mg<sup>2+</sup>. Finally, we characterized the kinetic properties of the enzyme using a design-of-experiment approach, revealing optimal activity at pH 7.6 and 41°C.</p></div><div><h3>Conclusions</h3><p>Although, <em>E. coli</em> has many advantages, such as rapid expression, high yields and low costs, this system was outperformed by BEVS for the production of a schistosome ALDH. BEVS therefore provides an opportunity for the expression and subsequent evaluation of schistosome enzymes as drug targets.</p><p><strong>How to cite:</strong> Harnischfeger J, Beutler M, Salzig D, et al. Biochemical characterization of the recombinant schistosome tegumental protein SmALDH_312 produced in <em>E. coli</em> and baculovirus expression vector system. Electron J Biotechnol 2021;54. https://doi.org/10.1016/j.ejbt.2021.08.002</p></div>","PeriodicalId":11529,"journal":{"name":"Electronic Journal of Biotechnology","volume":"54 ","pages":"Pages 26-36"},"PeriodicalIF":2.3000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejbt.2021.08.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0717345821000415","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Background
The heterologous expression of parasitic proteins is challenging because the sequence composition often differs significantly from host preferences. However, the production of such proteins is important because they are potential drug targets and can be screened for interactions with new lead compounds. Here we compared two expression systems for the production of an active recombinant aldehyde dehydrogenase (SmALDH_312) from Schistosoma mansoni, which causes the neglected tropical disease schistosomiasis.
Results
We produced SmALDH_312 successfully in the bacterium Escherichia coli and in the baculovirus expression vector system (BEVS). Both versions of the recombinant protein were found to be active in vitro, but the BEVS-derived enzyme showed 3.7-fold higher specific activity and was selected for further characterization. We investigated the influence of Mg2+, Ca2+ and Mn2+, and found out that the specific activity of the enzyme increased 1.5-fold in the presence of 0.5 mM Mg2+. Finally, we characterized the kinetic properties of the enzyme using a design-of-experiment approach, revealing optimal activity at pH 7.6 and 41°C.
Conclusions
Although, E. coli has many advantages, such as rapid expression, high yields and low costs, this system was outperformed by BEVS for the production of a schistosome ALDH. BEVS therefore provides an opportunity for the expression and subsequent evaluation of schistosome enzymes as drug targets.
How to cite: Harnischfeger J, Beutler M, Salzig D, et al. Biochemical characterization of the recombinant schistosome tegumental protein SmALDH_312 produced in E. coli and baculovirus expression vector system. Electron J Biotechnol 2021;54. https://doi.org/10.1016/j.ejbt.2021.08.002
寄生蛋白的异源表达具有挑战性,因为其序列组成往往与宿主偏好有很大差异。然而,这类蛋白质的生产是重要的,因为它们是潜在的药物靶点,可以筛选与新的先导化合物的相互作用。本文比较了两种表达系统对曼氏血吸虫活性重组醛脱氢酶(SmALDH_312)的表达效果。曼氏血吸虫是一种被忽视的热带病。结果SmALDH_312在大肠杆菌和杆状病毒表达载体系统(BEVS)中成功表达。两种版本的重组蛋白在体外都有活性,但bevs衍生的酶的比活性高出3.7倍,并被选中进行进一步的表征。我们研究了Mg2+、Ca2+和Mn2+的影响,发现在0.5 mM Mg2+的存在下,酶的比活性提高了1.5倍。最后,我们用实验设计的方法表征了酶的动力学性质,揭示了在pH 7.6和41°C下的最佳活性。结论大肠杆菌具有表达速度快、产率高、成本低等优点,但BEVS系统在血吸虫ALDH的制备上优于BEVS系统。因此,BEVS为血吸虫酶作为药物靶点的表达和后续评价提供了机会。引用方式:Harnischfeger J, Beutler M, Salzig D等。重组血吸虫被膜蛋白SmALDH_312在大肠杆菌和杆状病毒表达载体系统中的生化特性研究中国生物医学工程学报(英文版);2011;16。https://doi.org/10.1016/j.ejbt.2021.08.002
期刊介绍:
Electronic Journal of Biotechnology is an international scientific electronic journal, which publishes papers from all areas related to Biotechnology. It covers from molecular biology and the chemistry of biological processes to aquatic and earth environmental aspects, computational applications, policy and ethical issues directly related to Biotechnology.
The journal provides an effective way to publish research and review articles and short communications, video material, animation sequences and 3D are also accepted to support and enhance articles. The articles will be examined by a scientific committee and anonymous evaluators and published every two months in HTML and PDF formats (January 15th , March 15th, May 15th, July 15th, September 15th, November 15th).
The following areas are covered in the Journal:
• Animal Biotechnology
• Biofilms
• Bioinformatics
• Biomedicine
• Biopolicies of International Cooperation
• Biosafety
• Biotechnology Industry
• Biotechnology of Human Disorders
• Chemical Engineering
• Environmental Biotechnology
• Food Biotechnology
• Marine Biotechnology
• Microbial Biotechnology
• Molecular Biology and Genetics
•Nanobiotechnology
• Omics
• Plant Biotechnology
• Process Biotechnology
• Process Chemistry and Technology
• Tissue Engineering